Dosage : Syrup, Drops, Gargle
Contains : Chlorpheniramine Maleate + Phenylephrine in DPS form
Category : Cough & Cold Preparations / Nasal Decongestants
Uses : Nasal congestion during cold
Price :

Maxtra is a combination medicine used to relieve the symptoms of cold associated with fever; these may include nasal congestion, excess production of mucus, runny nose, etc.


Phenylephrine Belongs to the class of topical sympathomimetic agents used as nasal decongestants, ophthalmologic decongestants and used in the treatment of heart failure.


Maxtra is product of Emcure Pharmaceuticals. Emcure, headquartered at Pune in West India, is an Indian pharmaceutical company. The company’s products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Nasal congestion


Nasal congestion or “stuffy nose” occurs when nasal and adjacent tissues and blood vessels become swollen with excess fluid, causing a “stuffy” plugged feeling. Nasal congestion may or may not include a nasal discharge or “runny nose.”


Nasal congestion usually is just an annoyance for older children and adults. But nasal congestion can be serious for children whose sleep is disturbed by their nasal congestion, or for infants, who might have a hard time feeding as a result.


As directed by physician


As directed by physician

Adverse Reactions/ Side Effects

Significant: Reflex bradycardia, extravasation (IV); rebound miosis (ophthalmic); Cardiac disorders: Arrhythmia, ischemia, extrasystoles, palpitation, tachycardia. Eye disorders: Eye pain, irritation, stinging or burning sensation, blurred vision, photophobia, mydriasis, vitreous opacity (transient). Gastrointestinal disorders: Nausea, vomiting. Nervous system disorders: Headache, paresthesia,tremor, weakness. Psychiatric disorders: Anxiety, agitation, insomnia, nervousness, excitability. Renal and urinary disorders: Urinary retention (in males). Respiratory, thoracic and mediastinal disorders:Skin and subcutaneous tissue disorders: Blanching of skin, pallor, piloerection. Vascular disorders: Hypertension, hypertensive crisis.

Potentially Fatal: Cerebral haemorrhage, ventricular arrhythmia, myocardial infarction.

Warnings and Precautions

Patient with CV disease (e.g. ischaemic heart disease, pre-existing bradycardia, partial heart block, severe coronary artery disease, heart failure, cardiogenic shock), diabetes mellitus, asthma, arteriosclerosis, aneurysm, hypertension, narrow-angle glaucoma. Renal impairment (IV). Children. Elderly. Pregnancy (especially those with history of pre-eclampsia) and lactation. Patient Counselling Eye drops may cause temporary blurring of vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure.


Severe hypertension, ventricular tachycardia, severe hyperthyroidism. Ophthalmic (10% solution): Close-angle glaucoma. Children and elderly. Cold preparations should not be used in children <2 years. Concomitant or within 14 days of MAOI use (oral).

Drug Interactions

Concomitant use with adrenergic blocking agents (e.g. phentolamine), phenothiazine drugs (e.g. chlorpromazine) and amiodarone may cause antagonistic effects. May potentiate pressor effects of oxytocic drugs and CV depressant effects of inhalational anaesthetics (e.g. cyclopropane, halothane). May increase risk of arrythmias with cardiac glycosides and quinidine. May enhance the effects of anticholinergic drugs (e.g. TCAs).

Potentially Fatal: Concomitant use with MAOIs (or within 14 days of stopping MAOIs) may result in paroxysmal hypertension and fatal hyperthermia.


Symptoms: Headache, nausea, vomiting, paranoid psychosis, hallucinations, seizures, cerebral haemorrhage, palpitation, paraesthesia, reflex bradycardia, cardiac arrhythmia (e.g. ventricular tachycardia and extrasystoles), sensation of fullness in the head and tingling of extremities. Management: Symptomatic and supportive treatment. α-adrenergic blockers (e.g. phentolamine) may be used to treat severe hypertension.


Mechanism of Action

Phenylephrine is a sympathomimetic amine that has direct effect on α-adrenergic receptors and an indirect effect of releasing norepinephrine from its storage sites. Its main effect is systemic arterial vasoconstriction. Additionally, it produces local vasoconstriction on dilated arterioles of the conjunctiva and nasal mucosa.


If you are a healthcare practitioner and want additional material on the brand, disease, or molecule we have a few articles that can be hand-delivered by the company representative to you directly.